Robin Marcus is Marken’s Head of Global Decentralized Trials Market Development and has over 30 years of experience driving business optimization, championing innovation and generating aggressive revenue growth. She has successfully launched new products, divisions and companies that have exceeded corporate goals and built collaborative, high-performance teams to deliver results across the healthcare enterprise.
For the past 10 years, Robin has focused on the global expansion of decentralized clinical trial (DCT) services, including mobile clinical services, e-consent, eCOA/ePRO, telemedicine and ambulatory devices. Robin’s clinical background and experience working in pharma and biotech industries is critical in assessing and developing DCT strategies at the company, portfolio and study level. Prior to joining Marken, Robin was the Chief Strategy Officer at GlobalCare Clinical Trials and later an Executive Director focused on DCT Implementation during an acquisition by LabCorp Drug Development.
Understanding how site augmentation services could be leveraged to overcome challenges is not the responsibility of one entity. The most creative and effective solutions arise from collaboration among all stakeholders — sponsors, CROs, service providers, and research sites.